GSK3B and early-onset autosomal dominant Alzheimer disease: These results reflect the findings of Liu et al., who reported the inhibition of Cdk5 and GSK-3β activities, as well as reduction of Alzheimer's disease-like pathology, in senescence-accelerated mice [81].